Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders

Ewgeni Jakubovski; Jessica A. Johnson; Madeeha Nasir; Kirsten Müller-Vahl; Michael H. Bloch

doi:10.1002/da.22854

journal article Nov 26, 2018

Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders

Ewgeni Jakubovski

Jessica A. Johnson Madeeha Nasir Kirsten Müller-Vahl Michael H. Bloch

Depression and Anxiety Vol. 36 No. 3 pp. 198-212 · Wiley

View at Publisher Save 10.1002/da.22854

Topics

No keywords indexed for this article. Browse by subject →

References

86

[1]

Abramowitz "Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review" Journal of Consulting and Clinical Psychology (1997) 10.1037/0022-006x.65.1.44

[2]

Ackerman "Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder" Journal of Clinical Psychopharmacology (2002) 10.1097/00004714-200206000-00012

[3]

Allgulander "Paroxetine in social anxiety disorder: a randomized placebo-controlled study" Acta Psychiatrica Scandinavica (1999) 10.1111/j.1600-0447.1999.tb10845.x

[4]

Allgulander "Efficacy of sertraline in a 12-week trial for generalized anxiety disorder" American Journal of Psychiatry (2004) 10.1176/appi.ajp.161.9.1642

[5]

Allgulander "Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study" British Journal of Psychiatry (2001) 10.1192/bjp.179.1.15

[6]

Allgulander "Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine" Human Psychopharmacology (2004) 10.1002/hup.602

[7]

Asakura "Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study" International Journalof Neuropsychopharmacology (2007) 10.1017/s1461145706006602

[8]

Baldwin "Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology" Journal of Psychopharmacology (2005) 10.1177/0269881105059253

[9]

Baldwin "Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group" British Journal of Psychiatry (1999) 10.1192/bjp.175.2.120

[10]

Baldwin "Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study" British Journal of Psychiatry (2006) 10.1192/bjp.bp.105.012799

[11]

Ballenger "Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder" American Journal of Psychiatry (1998) 10.1176/ajp.155.1.36

[12]

Black "A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder" Archives of General Psychiatry (1993) 10.1001/archpsyc.1993.01820130046008

[13]

Bollini "Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials" British Journal of Psychiatry (1999) 10.1192/bjp.174.4.297

[14]

Book "Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder" Journal of Anxiety Disorders (2008) 10.1016/j.janxdis.2007.03.001

[15]

Bradwejn "Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study" British Journal of Psychiatry (2005) 10.1192/bjp.187.4.352

[16]

Brawman-Mintzer "Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study" Journal of Clinical Psychiatry (2006) 10.4088/jcp.v67n0603

[17]

Bridge "Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder" American Journal of Psychiatry (2009) 10.1176/appi.ajp.2008.08020247

[18]

Coric "Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder" Depression and Anxiety (2010) 10.1002/da.20695

[19]

Cox "Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: A meta-analysis" Journal of Behavior Therapy and Experimental Psychiatry (1993) 10.1016/0005-7916(93)90043-v

[20]

Davidson "Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder" Journal of Clinical Psychopharmacology (2004) 10.1097/01.jcp.0000106222.36344.96

[21]

Davidson "Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study" Depression and Anxiety (2004) 10.1002/da.10146

[22]

Davidson "Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder" Journal of Clinical Psychiatry (1999) 10.4088/jcp.v60n0805

[23]

Davidson "Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia" Archives of General Psychiatry (2004) 10.1001/archpsyc.61.10.1005

[24]

Davis "Update on the efficacy of pharmacotherapy for social anxiety disorder: A meta-analysis" Expert Opinion on Pharmacotherapy (2014) 10.1517/14656566.2014.955472

[25]

Fedoroff "Psychological and pharmacological treatments of social phobia: A meta-analysis" Journal of Clinical Psychopharmacology (2001) 10.1097/00004714-200106000-00011

[26]

Furmark "Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo" Biological Psychiatry (2005) 10.1016/j.biopsych.2005.03.029

[27]

Gelenberg "Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial" JAMA (2000) 10.1001/jama.283.23.3082

[28]

Greist "Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis" Archives of General Psychiatry (1995) 10.1001/archpsyc.1995.03950130053006

[29]

Hartford "Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial" International Clinical Psychopharmacology (2007) 10.1097/yic.0b013e32807fb1b2

[30]

Hedges "The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: A meta-analysis of double-blind, placebo-controlled trials" Journal of Psychopharmacology (2007) 10.1177/0269881106065102

[31]

Hoehn-Saric "Effect of fluvoxamine on panic disorder" Journal of Clinical Psychopharmacology (1993) 10.1097/00004714-199310000-00004

[32]

Hoffman "Anxiety disorders: A comprehensive review of pharmacotherapies" Mount Sinai Journal of Medicine (2008) 10.1002/msj.20041

[33]

Hofmann "Cognitive-behavioral therapy for adult anxiety disorders: A meta-analysis of randomized placebo-controlled trials" Journal of Clinical Psychiatry (2008) 10.4088/jcp.v69n0415

[34]

Issari "Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: A meta-analysis" Journal of Clinical Psychiatry (2016) 10.4088/jcp.14r09758

[35]

Jakubovski "Systematic review and meta-analysis: Dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder" American Journal of Psychiatry (2016) 10.1176/appi.ajp.2015.15030331

[36]

Kashima "Morphometric study of the rat exocrine pancreas after diversion of bile and pancreatic juice from the intestine" Gastroenterology (1988) 10.1016/s0016-5085(88)80085-4

[37]

Kasper "Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial" International Clinical Psychopharmacology (2009) 10.1097/yic.0b013e32831d7980

[38]

Kasper "Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study" British Journal of Psychiatry (2005) 10.1192/bjp.186.3.222

[39]

Kobak "Behavioral versus pharmacological treatments of obsessive compulsive disorder: A meta-analysis" Psychopharmacology (1998) 10.1007/s002130050558

[40]

Koponen "Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians" Primary Care Companion to The Journal of Clinical Psychiatry (2007) 10.4088/pcc.v09n0203

[41]

Lader "Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study" Depression and Anxiety (2004) 10.1002/da.20014

[42]

Lenox-Smith "A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care" British Journal of General Practice (2003)

[43]

Lenze "Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial" American Journal of Psychiatry (2005) 10.1176/appi.ajp.162.1.146

[44]

Lepola "Controlled-release paroxetine in the treatment of patients with social anxiety disorder" Journal of Clinical Psychiatry (2004) 10.4088/jcp.v65n0213

[45]

Liebowitz "A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder" Journal of Clinical Psychiatry (2009) 10.4088/jcp.08m04238

[46]

Liebowitz "Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study" Journal of Clinical Psychiatry (2003) 10.4088/jcp.v64n0708

[47]

Liebowitz "Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder" Archives of General Psychiatry (2005) 10.1001/archpsyc.62.2.190

[48]

Liebowitz "A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder" Journal of Clinical Psychiatry (2005) 10.4088/jcp.v66n0213

[49]

Liebowitz "A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder" Journal of Clinical Psychiatry (2002) 10.4088/jcp.v63n0113

[50]

Michelson "Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial" British Journal of Psychiatry (2001) 10.1192/bjp.179.6.514

Showing 50 of 86 references

Cited By

108

Embryonic Zebrafish Irritant-evoked Hyperlocomotion (EZIH) as a high-throughput behavioral model for nociception

Amelia A. Bunnell, Erin M. Marshall · 2025

Behavioural Brain Research

Anxiety-Reducing Effects of Lavender Essential Oil Inhalation: A Systematic Review

Onyoo Yoo, Sin-Ae Park · 2023

Healthcare

A Review of Ocular Complications Associated with Medications Used for Anxiety, Depression, and Stress

Paul A Constable, Dalia Al-Dasooqi · 2022

Clinical Optometry

Metrics

108

Citations

86

References

Details

Published: Nov 26, 2018
Vol/Issue: 36(3)
Pages: 198-212
License: View

Authors

E

Ewgeni Jakubovski

Department of Psychiatry; Social Psychiatry and Psychotherapy; Hannover Medical School; Hannover Germany

J

Jessica A. Johnson

Yale Child Study Center; Yale School of Medicine; Yale University; New Haven Connecticut

M

Madeeha Nasir

Yale Child Study Center; Yale School of Medicine; Yale University; New Haven Connecticut

K

Kirsten Müller-Vahl

Department of Psychiatry; Social Psychiatry and Psychotherapy; Hannover Medical School; Hannover Germany

M

Michael H. Bloch

Yale Child Study Center; Yale School of Medicine; Yale University; New Haven Connecticut; Department of Psychiatry; Yale School of Medicine; Yale University; New Haven Connecticut

Funding

National Institutes of Health

Deutsche Forschungsgemeinschaft Award: GZ MU 1527/3-1

National Institute of Mental Health Award: R01MH092293-01A1

the German Ministry of Education and Research Award: 01KG1421

the Kröner-Fresenius foundation, and Therapix Biosciences

Cite This Article

Ewgeni Jakubovski, Jessica A. Johnson, Madeeha Nasir, et al. (2018). Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. Depression and Anxiety, 36(3), 198-212. https://doi.org/10.1002/da.22854

Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders

You May Also Like